Citius Pharmaceuticals (NASDAQ:CTXR) Earns Buy Rating from D. Boral Capital

Citius Pharmaceuticals (NASDAQ:CTXR)‘s stock had its “buy” rating reissued by research analysts at D. Boral Capital in a research report issued to clients and investors on Thursday,Benzinga reports. They currently have a $9.00 target price on the stock.

Citius Pharmaceuticals Price Performance

Shares of NASDAQ:CTXR opened at $0.85 on Thursday. Citius Pharmaceuticals has a 1 year low of $0.65 and a 1 year high of $26.25. The business’s 50 day simple moving average is $1.07 and its 200 day simple moving average is $2.90.

Citius Pharmaceuticals (NASDAQ:CTXR) last released its earnings results on Wednesday, May 14th. The company reported ($1.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.08) by ($0.19). On average, equities analysts predict that Citius Pharmaceuticals will post -4.5 EPS for the current year.

Hedge Funds Weigh In On Citius Pharmaceuticals

Several large investors have recently bought and sold shares of the company. IFP Advisors Inc increased its stake in shares of Citius Pharmaceuticals by 21.2% in the fourth quarter. IFP Advisors Inc now owns 40,416 shares of the company’s stock valued at $162,000 after buying an additional 7,083 shares during the period. Fisher Asset Management LLC bought a new position in shares of Citius Pharmaceuticals in the fourth quarter valued at approximately $51,000. Finally, Tower Research Capital LLC TRC lifted its holdings in shares of Citius Pharmaceuticals by 103.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 8,212 shares of the company’s stock valued at $33,000 after purchasing an additional 4,168 shares in the last quarter. 16.88% of the stock is currently owned by institutional investors.

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.